Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 17Colorectal Neoplasms 6Stomach Neoplasms 4HER2-positive Breast Cancer 4Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Breast Diseases 1Biliary Tract Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

pembrolizumab 4Pemetrexed 3Paclitaxel 3Fulvestrant 2FANG vaccine 2Drug Therapy 2Carboplatin 2tucatinib 1trastuzumab deruxtecan 1seribantumab 1selinexor 1osimertinib 1gedatolisib 1dactolisib 1cobimetinib 1cemiplimab 1atezolizumab 1Watchful Waiting 1Trastuzumab 1Transurethral Resection of Prostate 1Trabectedin 1Therapeutics 1Sutures 1Radiation 1Quality of Life 1Pregnancy Tests 1Patient Reported Outcome Measures 1Oxaliplatin 1OSI 930 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Neoplasms × tucatinib × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡